Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 2, March-April, p. 255–261

doi: 10.17219/acem/40068

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Serum Heat Shock Protein 90 Alpha: A New Marker of Hypertension-Induced Endothelial Injury?

Katarzyna E. Skórzyńska-Dziduszko1,A,B,C,D,E,F, Anna Olszewska1,B,E,F, Monika Prendecka1,B,E,F, Teresa Małecka-Massalska1,A,B,E,F

1 Department of Human Physiology, Medical University of Lublin, Poland


Background. Hypertension-induced endothelial dysfunction is associated with an impaired bioavailability of nitric oxide regulated through interactions between nitric oxide synthase and heat shock protein-90 (Hsp-90). The role of Hsp-90 in the development of arterial hypertension remains unclear.
Objectives. The objective of the study was to evaluate serum concentrations of Hsp-90a in patients with arterial hypertension in comparison to their normotensive counterparts.
Material and Methods. The study was performed on 49 adults (mean age 55.6 years) with an elevated waist circumference. The individuals presented no subjective feeling of any disease, admitted no drug treatment for any condition, and had not previously been diagnosed with the metabolic syndrome. Patients were screened for arterial hypertension and other component disorders of the metabolic syndrome. Hsp-90a concentrations were evaluated by enzyme-linked immunosorbent assay (ELISA).
Results. Twenty-eight subjects were diagnosed with arterial hypertension, while 21 individuals had normal blood pressure. Twenty-five patients satisfied the metabolic syndrome diagnostic criteria. Hsp-90a concentrations were significantly higher (p = 0.002) in the individuals with arterial hypertension than in their normotensive counterparts (median ± interquartile range): 19.42 ng/mL ± 5.17 vs. 16.86 ng/mL ± 3.18. The concentrations of Hsp-90a correlated positively with systolic blood pressure (R = 0.39; p = 0.005) and diastolic blood pressure (R = 0.29; p = 0.046).
Conclusion. An increase in Hsp-90a concentrations in patients with arterial hypertension may be a compensatory mechanism for the impaired bioavailability of nitric oxide. The role of Hsp-90a as an early marker of hypertension-associated endothelial injury should be confirmed in further studies on a larger group of patients.

Key words

arterial hypertension, metabolic syndrome, endothelial dysfunction, nitric oxide, heat shock protein

References (22)

  1. Chatterjee A, Black SM, Catravas JD: Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul Pharmacol 2008, 49, 134–140.
  2. Giles TD, Sander GE, Nossaman BD, Kadowitz PJ: Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. J Clin Hypertens (Greenwich) 2012, 14, 198–205.
  3. Michel T, Vanhoutte PM: Cellular signaling and NO production. Pflugers Arch 2010, 459, 807–816.
  4. Bauer V, Sotníková R: Nitric oxide – the endothelium-derived relaxing factor and its role in endothelial functions. Gen Physiol Biophys 2010, 29, 319–340.
  5. Richter K, Buchner J: Hsp90: chaperoning signal transduction. J Cell Physiol 2001, 188, 281–290.
  6. Pratt WB, Toft DO: Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 2003, 228, 111–133.
  7. Csermely P, Schnaider T, Soti C, Prohászka Z, Nardai G: The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998, 79, 129–168.
  8. Jérôme V, Vourc’h C, Baulieu EE, Catelli MG: Cell cycle regulation of the chicken hsp90 alpha expression. Exp Cell Res 1993, 205, 44–51.
  9. Yufu Y, Nishimura J, Nawata H: High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res 1992, 16, 597–605.
  10. Jérôme V, Léger J, Devin J, Baulieu EE, Catelli MG: Growth factors acting via tyrosine kinase receptors induce HSP90 alpha gene expression. Growth Factors 1991, 4, 317–327.
  11. Bertram J, Palfner K, Hiddemann W, Kneba M: Increase of P-glycoprotein-mediated drug resistance by hsp 90 beta. Anticancer Drugs 1996, 7, 838–845.
  12. Grammatikakis N, Vultur A, Ramana CV, Siganou A, Schweinfest CW, Watson DK, Raptis L: The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem 2002, 277, 8312–8320.
  13. Pritchard KA Jr, Ackerman AW, Gross ER, Stepp DW, Shi Y, Fontana JT, Baker JE, Sessa WC: Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J Biol Chem 2001, 276, 17621–17624.
  14. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity: Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemi
  15. Wyrzykowski B, Zdrojewski T, Sygnowska E, Biela U, Drygas W, Tykarski A, Tendera M, Broda G: Epidemiology of metabolic syndrome in Poland. Results of the WOBASZ program. Kardiol Pol 2005, 63, 6, Suppl 4, 641–644.
  16. Piech A, Dessy C, Havaux X, Feron O, Balligand JL: Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. Cardiovasc Res 2003, 57, 456–467.
  17. Oyama J, Maeda T, Sasaki M, Higuchi Y, Node K, Makino N: Repetitive hyperthermia attenuates progression of left ventricular hypertrophy and increases telomerase activity in hypertensive rats. Am J Physiol Heart Circ Physiol 2012, 302, 2092–2101.
  18. Zhou J, Ando H, Macova M, Dou J, Saavedra JM: Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 2005, 25, 878–886.
  19. Moleda L, Jurzik L, Froh M, Gäbele E, Hellerbrand C, Straub RH, Schölmerich J, Wiest R: Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension. World J Gastroenterol 2010, 16, 1837–1844.
  20. Hassanpour H, Afzali A, Bahadoran SH: Diminished gene expression of cardiac heat shock proteins in pulmonary hypertensive chickens. Br Poult Sci 2013, 54, 581–586.
  21. Komatsuda A, Wakuil H, Imai H, Itoh H, Yasuda T, Miura AB: Expression of 90-kDa heat shock protein within regenerative tubular cells in a patient with acute oliguric renal failure due to malignant hypertension. Ren Fail 1999, 21, 113–117.
  22. Tiss A, Khadir A, Abubaker J, Abu-Farha M, Al-Khairi I, Cherian P, John J, Kavalakatt S, Warsame S, Al-Ghimlas F, Elkum N, Behbehani K, Dermime S, Dehbi M: Immunohistochemical profiling of the heat shock response in obese non-diabetic subjects revealed impaired expression of heat shock proteins in the adipose tissue. Lipids Health Dis 2014, 13, 106.